Smashing a four-day captivating streak, U.S. stocks finished lower on Friday, for the S&P 500 and Dow industrials, but equities kept up rock-hard weekly gains.
Despite the positive turn in the markets last week, this week has already brought a whole new set of problems to meditate on investors’ minds, beginning with Sunday’s snap vote in Greece, which rumor has it that enough of the pain of austerity. Voters want to return to the past by rolling back austerity measures and thumbing their collective nose at the Euro-zone and the broader international community of lenders. In reaction, the euro fell even further than it did in the face of the ECB’s incentive declaration last week.
Biotechnology Sector - A Shining Star:
Biotechnology is the utilization of biological processes for industrial and other purposes, particularly the genetic manipulation of microorganisms for the production of antibiotics, hormones, etc., while investors in this industry expect for is a company that can get through the research and clinical trials and materialize with a safe and effective product approved by the relevant health authorities.
Outlining favorable view on biotech, Brenthurst Wealth said:
“The biotechnology industry has blown many other sectors out of the water in the past two years and keep ons to grow at a phenomenal pace as the executives and researchers at these companies push the frontiers of medical science.”
The Nasdaq biotech index is up 60% over the last six months.
In biotech sector, Array Biopharma (NASDAQ:ARRY), opened the session at $5.25, remained amid the day range of $5.24 - $7.58, and closed the session at $7.11. The stock showed a positive performance of 40.79% in previous trading session. Array Biopharma, recently declared that it has reached a definitive contract with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development. This contract is conditional on the closing of transactions declared by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the contract remains subject to the receipt of regulatory approvals.
Array Biopharma (ARRY) a biopharmaceutical organization, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Catalyst Pharmaceutical Partners, (NASDAQ:CPRX), jumped up 6.62% and closed at $3.06. So far in three months, the stock is up 18.6%. The 52-week range for the stock is $1.70 and $3.49. Catalyst Pharmaceutical Partners, recently declared the organization’s 2015 goals for its product portfolio. The organization hosted 1×1 meeting in conjunction with The Trout Group Management Access Conference in San Francisco, January 12-15.
Catalyst Pharmaceutical Partners, (CPRX) operates as development-stage specialty pharmaceutical company. The organization focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
VIVUS, Inc. (NASDAQ:VVUS) the stock escalated 6.20% and closed the session at $2.74. The beta of the stock remained 1.15. The stock 52 week rang $2.56 to $8.36.
VIVUS, Inc. (NASDAQ:VVUS) a biopharmaceutical organization, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union.
Trinity Biotech plc (ADR) (NASDAQ:TRIB) gained volume of 196,577 shares, while the average volume remained 114,812.00 shares. The stock advanced 6.20% and finished the session Friday at $20.05.
Trinity Biotech plc (ADR) (NASDAQ:TRIB) acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. It offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as bacterial, fungal, parasitic, and viral diseases; autoimmune disorders; products for the in-vitro diagnostic testing for haemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes; Hb variants for the detection of Hemoglobinapothies; and reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney diseases, and haemolytic anaemia.
Gilead Sciences, Inc. (NASDAQ:GILD) traded with volume of 9.6 million shares in the prior session and the average volume of the stock remained 19.51 million shares. The stock showed a positive movement of 0.38% and closed its session at $105.54. Gilead Sciences, recently declared that the organization has expanded its hepatitis C generic licensing contracts to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.
Gilead Sciences, (GILD) a biopharmaceutical organization, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific.
Juno Therapeutics Inc (NASDAQ:JUNO) exchanged 2.2 million shares and the average volume remained 3.35 million shares. The stock dropped -5.88% and closed the session at $41.30.
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical organization, involves in developing cell-based cancer immunotherapies. The organization develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Array Biopharma, NASDAQ:ARRY,Catalyst Pharmaceutical Partners, NASDAQ:CPRX, VIVUS, NASDAQ:VVUS, Trinity Biotech, NASDAQ:TRIB, Gilead Sciences, NASDAQ:GILD, Juno Therapeutics, NASDAQ:JUNO,
